

[Click here to view linked References](#)

1
2
3 **Effect of sprayable, highly adhesive hydrophobized gelatin microparticles on esophageal stenosis**

4
5
6 **after endoscopic submucosal dissection: an experimental study in a swine model**

7
8
9
10
11
12 Hiroki Yano, MD¹, Fumisato Sasaki, MD, PhD^{1*}, Hidehito Maeda, MD, PhD¹, Shohei Uehara, MD¹,

13
14
15 Masayuki Kabayama, MD, PhD¹, Yusuke Fujino, MD¹, Akihito Tanaka, MD, PhD¹, Makoto Hinokuchi,

16
17
18 MD, PhD¹, Shiho Arima, MD, PhD¹, Shinichi Hashimoto, MD, PhD¹, Shuji Kanmura, MD, PhD¹, Shima

19
20
21 Ito, PhD^{2,3}, Akihiro Nishiguchi, PhD², Tetsushi Taguchi, PhD^{2,3}, Akio Ido, MD, PhD¹

22
23
24
25
26
27
28 ¹Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences,

29
30
31 Kagoshima, Japan

32
33
34
35 ²Research Center for Macromolecules and Biomaterials, National Institute for Materials Science, Tsukuba,

36
37
38 Japan

39
40
41 ³Graduate School of Science and Technology, Degree Programs in Pure and Applied Sciences, University

42
43
44 of Tsukuba, Tsukuba, Japan

45
46
47
48
49
50
51 ***Corresponding author:** Fumisato Sasaki, MD, PhD

52
53
54
55
56
57 1

58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences,

8-35-1, Sakuragaoka, Kagoshima 890-8520, Japan

Phone: +81-99-275-5326

Fax: +81-99-264-3504

E-mail: bungohs@m2.kufm.kagoshima-u.ac.jp

Abstract

Background: Esophageal mucosal resection for superficial esophageal cancer can lead to postoperative esophageal stricture, with current preventive measures being insufficient. Sprayable wound dressings containing hydrophobized microparticles exhibit strong adhesion. This study aimed to investigate the preventive effects of hydrophobized microparticles on esophageal stenosis following endoscopic submucosal dissection.

Methods: Circumferential esophageal endoscopic submucosal dissection was performed on miniature swine (n=6). Swine were categorized into two groups: those sprayed with hydrophobized microparticles (sprayed group) and those not sprayed (non-sprayed group). Hydrophobized microparticles were sprayed onto the sprayed group on Days 0, 3, and 7 of endoscopic submucosal dissection. The non-sprayed group underwent endoscopy on the same days. Esophageal stricture rate, submucosal inflammatory cell infiltration, submucosal fibrosis, and thickening of the muscular layer were compared between the groups on Day 14 of endoscopic submucosal dissection.

Results: Spraying of hydrophobized microparticles was easily performed using an existing endoscopic spraying device. The esophageal stricture rate was significantly lower in the sprayed group than in the non-sprayed group (76.1% versus 90.6%, $p<0.05$). The sprayed group showed suppression of inflammatory cell infiltration in the submucosal layer ($p<0.01$) and thickening of the muscular layer ($p<0.01$).

Conclusions: Sprayable tissue-adhesive hydrophobized microparticles reduce the stricture rate after esophageal ESD by inhibiting inflammatory cell infiltration, submucosal fibrosis, and thickening of the muscular layer. The use of hydrophobized microparticles for preventing post-endoscopic submucosal dissection esophageal stenosis offers a promising avenue for clinical applications in endoscopic procedures, potentially improving patient outcomes.

Keywords: endoscopic submucosal dissection; esophageal stricture; inflammation; gelatin; swine

Introduction

Endoscopic submucosal dissection (ESD) is a well-established and widely adopted technique for endoscopic resection, increasingly utilized worldwide [1]. ESD has enabled resection of extensive lesions; however, several adverse events have been reported, with esophageal stenosis being the most common [1].

Extensive esophageal mucosal resection for superficial esophageal cancer often results in postoperative esophageal stricture, significantly decreasing patients' quality of life [2]. Such postoperative stricture is particularly frequent in cases of extensive dissection of approximately $\geq 75\%$ of the circumference, with the incidence of postoperative strictures for circumferential lesions possibly reaching 100% [3, 4]. Guidelines for esophageal cancer published in Japan in 2022 strongly recommend preventive measures following endoscopic treatment of esophageal cancer [5]. However, despite various stenosis-preventive measures, preventive measures for patients undergoing full circumferential resection are still insufficient.

In our previous study, a hexanoyl (Hx:C6) group-modified alkaline-treated gelatin porous film (HAG) induced proper healing by decreasing submucosal fibrosis in post-ESD gastric ulcers in miniature swine [6, 7]. Thereafter, we developed a sprayable wound dressing comprising multifunctional hydrophobized microparticles (hMPs) derived from swine gelatin. This dressing showed strong tissue adhesion in wet environments and effectively suppressed submucosal fibrosis in post-ESD gastric ulcers in miniature swine [8]. Furthermore, we successfully developed a sprayable wound dressing made with fine particles of pollock gelatin [9]. We have previously also reported the strong adhesive effect of hMPs in terms of closing gastrointestinal perforation models [9, 10]. We have also demonstrated an anti-inflammatory effect on post-ESD ulcers in a duodenal ESD animal model [10].

We hypothesized that highly adhesive hMPs would effectively prevent strictures after total esophageal ESD by tightly adhering to post-ESD ulcers and suppressing inflammation and fibrosis in the submucosal and muscle layers. Here, we aimed to investigate the efficacy of hMPs in preventing stenosis after esophageal ESD.

Materials and Methods

Experimental animals

Six miniature swine (male or female, 6 months old; 11–15 kg; Kagoshima Miniature Swine Research Center, Kagoshima, Japan) were used in this study. Premedication for these miniature swine involved intramuscular injections of 15 mg/kg ketamine (Daiichi Sankyo Propharma, Tokyo, Japan) and 2 mg/kg xylazine (Bayer Yakuhin,

Osaka, Japan), followed by sevoflurane inhalation anesthesia (Maruishi Pharmaceutical, Osaka, Japan). An endotracheal tube (100/199/065; Smith Medical Japan, Tokyo, Japan) was inserted, and anesthesia was maintained using sevoflurane. The animals were allowed free access to water on the day of ESD and solid food the following day.

Ethical statement

All experiments were approved by the Animal Care and Use Committee of Kagoshima University (approval number: MD 20015). Animal care, housing, and surgery were performed in accordance with the guidelines and regulations of the Committee for Animal Research at Kagoshima University, Japan.

hMPs

Hydrophobically modified Alaska pollock gelatin (hm-ApGln) was prepared by reductive amination between gelatin and aldehyde [11]. hMPs were prepared using a coacervation method in a water/ethanol mixed solvent [12]. The optimized alkyl chain length (decyl groups, C10) and degree of substitution (43% with amino groups in ApGln) of the hydrophobic groups improved the mechanical strength of the hydrogel formed by hydration and fusion of the microparticles. Scanning electron microscopy confirmed that the obtained hMPs possessed micrometer-sized particles (Figure 1).

ESD procedure

We established an ESD-induced esophageal stricture model. A full circumferential artificial ulcer with a 20-mm-long diameter was created at the lower esophagus [3 cm from the esophagogastric (EG) junction to the mouth] using the ESD technique. Artificial esophageal ulcers were created by an expert endoscopist who performed ESD using an upper gastrointestinal endoscope (GIF-Q260J; Olympus, Tokyo, Japan) and video scope system (EVIS LUCERA CV-260SL; Olympus). A glycerin solution containing small amounts of indigo carmine (glycerol injection; Hikari Pharmaceutical, Tokyo, Japan) was injected into the submucosa. The mucosa and submucosal layers were incised using an electric knife (Hook Knife J, KD-625LR; Olympus) and an electrosurgical generator (Pulse Cut Fast mode, 30 W, ESG-100; Olympus) (Figure 2a). The diameter of the ulcer was measured using forceps (M2-K4; Olympus).

Delivery of hMPs

1 hMPs (200 mg) were packed into small vials. A battery-powered Alto shooter endoscopic injector (Alto Shooter
2 Kaigen, Tokyo, Japan), which can be used to apply powdered drugs, was used to spray the hMPs. A small vial of
3 hMPs was attached directly to the Alto shooter, and the nozzle was removed from the endoscope duct and sprayed
4 on the ulcer ([Online Resource 1](#)). The anterior, posterior, right, and left walls of circumferentially resected
5 esophageal ulcers were sprayed. Thus, 800 mg of hMPs (four vials) were used per ulcer.
6
7
8
9
10
11
12

Study schedule

13 The swine were divided into the sprayed and non-sprayed groups, and hMPs (800 mg/ulcer) were sprayed on the
14 sprayed group on Days 0, 3, and 7 of ESD. The non-sprayed group underwent endoscopy on the same days. In a
15 previous study on HAG developed before hMPs [6], HAG remained on the ulcer surface on day 3 after gastric
16 ESD; however, on day 7, it did not remain on the ulcer surface but in the granulation tissue. Based on these results,
17 we performed hMPs spraying on days 3 and 7 after esophageal ESD in this study with the expectation of residual
18 and higher efficacy. In this study, the animals were carefully observed for vomiting. If vomiting occurred, the swine
19 were offered non-solid foods. All efforts were made to minimize animal suffering. All miniature swine were
20 sacrificed on Day 14 of ESD by intravenous administration of a lethal dose of sodium pentobarbital (Kyoritsu
21 Seiyaku Co., Ltd., Tokyo, Japan). A histological evaluation was performed. (Figure 2b)
22
23
24
25
26
27
28
29
30
31
32
33
34
35

Evaluation of esophageal stricture rate

36 Because it was difficult to quantitatively analyze an esophageal stricture using endoscopic video images, each
37 stricture was evaluated on the basis of the stricture rates of the resected sample after fixation. The resected
38 esophageal specimen was pasted and fixed, and the stenosis rate was derived [13, 14]. Specifically, stricture rate
39 was evaluated as the ratio of the diameter of the most stenotic tubular structure to that of the normal area located
40 2 cm toward the mouth from the most stenotic area of the esophageal post-ESD ulcer. The diameters of the normal
41 and most stenotic areas were measured using ImageJ version 1.52u (National Institutes of Health, Bethesda, MD,
42 USA).
43
44
45
46
47
48
49
50
51
52
53

Histological analyses

1 Specimens were fixed in 10% neutral-buffered formalin (Kenei Pharmaceutical, Osaka, Japan) for 48 hours, and
2 each lesion was sliced at 4-mm intervals. The slices were then embedded in a paraffin block, cut into 2- μ m-thick
3 sections, and stained with hematoxylin and eosin (H&E) or Azan. Inflammatory cells infiltrating the submucosal
4 layers in 12 random fields of view (400x magnification) were counted in the H&E-stained tissues under a
5 microscope. Damage to the muscularis propria was evaluated using Azan staining. The thickness of the muscularis
6 propria was quantified on the basis of the ratio of the muscularis propria thickness in the ulcerated part (U) to that
7 of the non-ulcerated (NU) part (U/NU) [6]
8
9
10
11
12

13 ***Immunohistochemistry***

14 Immunohistochemical staining was performed to evaluate fibrosis in the submucosa.

15
16 Fibrosis was determined using anti-tissue inhibitor of metalloproteinases-1 (TIMP-1) antibody diluted 1:8000
17 (AbCam, Cambridge, MA, USA), anti-matrix metalloproteinase-2 (MMP-2) antibody diluted 1:1000 (AbCam),
18 and anti-matrix metalloproteinase-9 (MMP-9) antibody diluted 1:500 (AbCam). Similar to the counting of
19 inflammatory cells, positively expressing cells infiltrating the submucosa were counted in 12 randomly selected
20 fields of view (400x magnification). To compare the balance between tissue inhibitor of metalloproteinases
21 (TIMPs) and metalloproteinases (MMPs), the ratio was calculated by dividing the number of TIMP-1-positive-
22 expressing cells by the number of MMP-2- and MMP-9-positive-expressing cells.
23
24
25
26
27
28
29
30
31
32
33
34
35

36 ***Statistical analyses***

37
38 The statistical significance of differences between the two groups was calculated using the Student's *t*-test or
39 Mann–Whitney U test, depending on the results of the Kolmogorov–Smirnov test for normality. Statistical
40 significance was set at $p < 0.05$. All statistical analyses were performed using EZR (version 1.54; Saitama Medical
41 Center, Jichi Medical University, Saitama, Japan) [15] and a graphical user interface for R (version 2.13.0; R
42 Foundation for Statistical Computing, Vienna, Austria).
43
44
45
46
47
48
49

50 **Results**

51 ***hMPs can reduce the esophageal stricture rate***

52
53 ESD was performed safely in all swine without any adverse events. The esophagus of all swine was observed
54 endoscopically on Days 3, 7, and 14 of ESD. The endoscope could not pass through the stenosis in either group
55
56
57
58
59
60
61
62
63
64
65

1 because of severe esophageal stricture. Endoscopically, the strictures were more severe in the non-sprayed group
2 than in the sprayed group (Online Resource 2). To accurately evaluate the stenosis rate, the esophageal stenosis
3 rate was compared with macroscopic findings after sacrifice on Day 14. The esophageal stricture rate was
4 significantly lower in the sprayed group than in the non-sprayed group (76.11%±5.03% vs. 90.65%±1.00%,
5 respectively; p<0.05) (Figure 3).
6
7
8
9

10 ***Histological evaluation***

11
12 Histological observation of the submucosal tissues after 14 days of ESD showed that the number of invaded
13 inflammatory cells was lower in the tissues in the sprayed group than in the non-sprayed group (415.36±16.76
14 /HPF vs. 559.97±5.50 /HPF, respectively; p<0.01) (Figure 4). Thickening of the muscular layer was significantly
15 suppressed in the sprayed group compared with that in the non-sprayed group (U/NU ratio, 0.90±0.16 vs.
16 1.79±0.09, respectively; p<0.01) (Figure 5). Additionally, the ratio of TIMP-1- to MMP-2-positive cells in the
17 submucosal layer (TIMP-1/MMP-2 ratio) was significantly lower in the sprayed group than in the non-sprayed
18 group (0.39±0.09 vs. 1.97±0.30, respectively; p<0.01). Similarly, the ratio of TIMP-1- to MMP-9-positive cells in
19 the submucosal layer (TIMP-1/MMP-9 ratio) was significantly lower in the sprayed group than in the non-sprayed
20 group (1.17±0.43 vs. 4.97±1.16, respectively; p<0.05) (Figure 6).
21
22
23
24
25
26
27
28
29
30
31
32
33

34 **Discussion**

35
36 We showed that hMPs can efficiently suppress inflammation, inhibit fibrosis in submucosal tissues, and suppress
37 the thickening of the muscular layer via physical and biochemical interactions after ESD. Consequently, we
38 succeeded in showing that hMPs reduced the stricture rate after esophageal ESD (Figure 7).
39
40
41

42 During the wound healing process, such as in the case of ESD ulcers, inflammatory cells migrate to the
43 ulcer area and form granulation tissues. Subsequently, fibroblasts, which are inflammatory cells, differentiate into
44 myofibroblasts that contract ulcers. Fibroblasts are also known to produce collagen, contributing to fibrosis and
45 the formation of hard scars [16].
46
47
48
49

50 The application of hMPs is believed to act as a barrier, preventing external stimuli and food from reaching
51 the ulcer base; this barrier effect may lead to a reduction in the number of inflammatory cells, including fibroblasts,
52 migrating to the ulcer site. Consequently, by inhibiting collagen production, ulcer contraction and fibrosis are
53 suppressed. hMPs have the potential to decrease excess scarring through physical and biochemical interactions
54
55
56
57
58
59
60
61
62
63
64
65

1 after ESD [10]. The present results indicate that hMPs may be useful in preventing stricture after esophageal ESD
2 by reducing damage to the muscularis propria and suppressing the thickening of the muscular layer (Figure 5).
3

4 Various methods have been employed to prevent postoperative stricture; however, their effectiveness is
5 limited [17, 18]. In this regard, technologies for stricture prevention after ESD of esophageal neoplasias are
6 emerging [19]. Collagen patches [14], autologous skin epidermal cell sheets [13], stomach mucosa transplantation
7 [20], amniotic membrane grafts [21], and metal stents treated with extracellular matrix (ECM) and autologous
8 platelet-rich plasma [22] are useful postoperative stricture mitigation methods. However, their clinical usefulness
9 for post-ESD esophageal stenosis is unclear. We previously reported that HAG induces proper healing by
10 decreasing inflammation in post-ESD gastric ulcers in miniature swine [6, 7]. Although HAG has strong self-
11 adhesiveness, an anti-inflammatory effect, and an anti-fibrotic effect, its delivery to the esophagus via an
12 endoscope is difficult. Therefore, we developed a sprayable wound dressing comprising hMPs made of swine
13 gelatin that showed strong tissue adhesion in wet environments and effectively suppressed inflammation in rat skin
14 ulcers and post-ESD gastric ulcers in miniature swine [8]. Ito et al. developed a sprayable wound dressing
15 comprising hMPs derived from Alaska pollock gelatin [9]. The advantages of hMPs over other methods for
16 preventing stenosis include ease of use and straightforward delivery to the ulcer site. This study utilized a spray
17 formulation for the hMPs dosage form. In a previous study [6], a sheet formulation was employed. However, in
18 the esophagus, which has a narrow lumen, applying the sheet to the optimal site was challenging due to its adhesive
19 properties. Therefore, the sheet formulation was replaced with a spray formulation. Previously, we found that the
20 anti-inflammatory effects of hMPs made of Alaska pollock gelatin, which gels quickly in swine models, were
21 similar to those of hMPs derived from swine gelatin [10]. Here, the anti-inflammatory effects of hMPs made of
22 Alaska pollock gelatin were also demonstrated in esophageal ulcers in miniature swine (Figure 4).
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 In this study, the use of hMPs decreased the TIMP-1/MMP-2 and TIMP-1/MMP-9 ratios (Figure 6).
43 TIMP-1 and MMP are fibrosis-related proteins. To the best of our knowledge, no studies have reported on TIMP-
44 1 expression in esophageal tissues; however, it is believed that an increase in TIMP-1 expression suppresses MMP
45 activity in liver tissues, resulting in collagen deposition and the promotion of liver fibrosis [23]. In healthy liver
46 tissues, a balance between TIMPs and MMPs controls the removal and assembly of the ECM [24]. During the
47 wound-healing process, an imbalance between TIMPs and MMPs during the remodeling phase leads to excessive
48 fibrosis of ECM components and promotes the formation of permanent fibrotic scars [25]. Erlewyn-Lajeunesse et
49 al. examined the processes involved in airway remodeling during wheezing by measuring the TIMP-1-to-MMP-9
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 ratio [26]. MMP-9 and MMP-2 are gelatinases of the MMP family that degrade type IV collagen and gelatin
2 substrates [27, 28]. TIMP-1 is a natural suppressor of MMP-9 and MMP-2 [29]. Previous studies have used a
3 combination of MMP-2 and MMP-9 as MMPs suppressed by TIMP-1 [30], and we performed
4 immunohistochemical staining for these MMPs in our study. TIMP-1 expression was suppressed compared with
5 MMP-9 and MMP-2 expressions in the sprayed group. A TIMP-1/MMPs ratio that favors MMPs may prevent
6 fibrosis due to ECM deposition. In other words, hMPs spraying is believed to maintain the balance between TIMP-
7 1 and MMPs, resulting in ulcer healing with reduced fibrosis and stricture prevention by inhibiting excessive
8 contraction.
9

10
11
12
13
14
15
16 Steroids, currently widely used to prevent stricture after esophageal ESD, are believed to prevent
17 esophageal stricture by suppressing inflammation and inhibiting fibroblast proliferation and collagen formation,
18 thereby reducing scarring [31]. Both steroids and hMPs share the common feature of suppressing inflammation,
19 fibroblast proliferation, and collagen formation in the submucosal to muscular layers. We plan to conduct future
20 studies using a combination of steroids and hMPs.
21
22
23
24
25

26 This study has some limitations. First, it was conducted using a small number of animals. The use of
27 miniature swine, which are medium to large animals, made it challenging to utilize a larger sample size for this
28 experiment. Second, the long-term effect of hMPs on post-ESD ulcers was not monitored. Further studies are
29 required to examine the long-term anti-fibrotic and stenosis-preventive effects of hMPs on the submucosa. Third,
30 a very strong stricture in occurred during full circumferential esophageal ESD in this miniature swine model. In
31 this study, the endoscope could not pass through the esophageal stricture in a miniature swine full circumferential
32 ESD because it was unexpectedly severe. Post-ESD stricture in miniature pigs may be more severe than in humans;
33 however, completely preventing esophageal stricture with hMP alone may be difficult. We plan to investigate the
34 efficacy of hMPs in partial esophageal ESD and in combination with steroids. Fourth, there is a lack of studies
35 addressing the safety of hMPs in humans. However, hMPs stimulate macrophages to produce MMP2, which
36 promotes the degradation of hMPs to peptides. Gelatin itself is not immunogenic, and its degradation by MMP2
37 to peptides is considered safe [32]. Fifth, we had not been able to examine in detail how long hMPs remain in the
38 tissues after spraying. Although we should have evaluated the persistence and dosage of hMPs and determined the
39 administration schedule, we could not conduct multiple studies because we used medium-sized animals (miniature
40 pigs) in this study. In this study, all miniature swine were sacrificed at day 14 post-ESD, and no hMPs remained
41 in the histological findings at that time. In conclusion, our results suggest that hMPs reduce the stricture rate after
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

esophageal ESD by inhibiting inflammatory cell infiltration, submucosal fibrosis, and thickening of the muscular layer. With further studies in animal models and clinical trials in humans, hMPs may prove beneficial in clinical practice for preventing postoperative strictures after esophageal ESD.

Acknowledgments

This work was supported by the Laboratory Animal Science Research Support Center, Institute for Research Promotion, Kagoshima University, Japan.

Ethical statement

All institutional and national guidelines for the care and use of laboratory animals were followed.

Conflict of interest

Hiroki Yano, Fumisato Sasaki, Hidehito Maeda, Shohei Uehara, Masayuki Kabayama, Yusuke Fujino, Akihito Tanaka, Makoto Hinokuchi, Shiho Arima, Shinichi Hashimoto, Shuji Kanmura, Shima Ito, Akihiro Nishiguchi, Tetsushi Taguchi, and Akio Ido declare that they have no conflict of interest.

Funding sources

This work was supported by the Translational Research Program TR-SPRINT (Strategic PRomotion for practical application of INnovative medical Technology) of the Japan Agency of Medical Research and Development (grant number [no.]: 20 lm0203114h0001) and the Japan Society for the Promotion of Science KAKENHI (grant nos.: 19K17467 and 20H0247).

Author contributions

Conception and design: Fumisato Sasaki; Analysis and interpretation of the data: Hiroki Yano and Fumisato Sasaki; Drafting of the article: Hiroki Yano, Fumisato Sasaki, and Akio Ido; Critical revision of the article for important intellectual content: Makoto Hinokuchi, Shiho Arima, Shinichi Hashimoto, Shuji Kanmura, and Akio Ido; Final approval of the article: All authors.

Data statement

11

1
2 The raw data supporting the conclusion of this article will be made available by the authors, without undue
3 reservation.
4

5 6 **References**

- 7
8 1. ASGE Technology Committee, Maple JT, Abu Dayyeh BK, et al. Endoscopic submucosal dissection.
9
10 Gastrointest Endosc. 2015;81:1311–25. <https://doi.org/10.1016/j.gie.2014.12.010>
11
- 12 2. Ohki T, Yamato M, Murakami D, et al. Treatment of oesophageal ulcerations using endoscopic
13
14 transplantation of tissue-engineered autologous oral mucosal epithelial cell sheets in a canine model. Gut.
15
16 2006;55:1704–10. <https://doi.org/10.1136/gut.2005.088518>
17
- 18 3. Yamashina T, Ishihara R, Uedo N, et al. Safety and curative ability of endoscopic submucosal dissection
19
20 for superficial esophageal cancers at least 50 mm in diameter. Dig Endosc. 2012;24:220–5.
21
22 <https://doi.org/10.1111/j.1443-1661.2011.01215.x>
23
- 24 4. Funakawa K, Uto H, Sasaki F, et al. Effect of endoscopic submucosal dissection for superficial esophageal
25
26 neoplasms and risk factors for postoperative stricture. Med (Baltim). 2015;94:e373.
27
28 <https://doi.org/10.1097/MD.0000000000000373>
29
- 30 5. Kitagawa Y, Ishihara R, Ishikawa H, et al. Esophageal cancer practice guidelines 2022 edited by the Japan
31
32 esophageal society: part 1. Esophagus. 2023;20:343–72. <https://doi.org/10.1007/s10388-023-00993-2>
33
- 34 6. Maeda H, Sasaki F, Morinaga Y, et al. Covering post-endoscopic submucosal dissection ulcers in
35
36 miniature swine with hexanoyl (Hx:C6) group-modified alkaline-treated gelatin porous film (HAG)
37
38 induces proper healing by decreasing inflammation and fibrosis. Digestion. 2021;102:415–27.
39
40 <https://doi.org/10.1159/000509056>
41
- 42 7. Yoshizawa K, Mizuta R, Taguchi T. Enhanced angiogenesis of growth factor-free porous biodegradable
43
44 adhesive made with hexanoyl group-modified gelatin. Biomaterials. 2015;63:14–23.
45
46 <https://doi.org/10.1016/j.biomaterials.2015.06.003>
47
- 48 8. Nishiguchi A, Sasaki F, Maeda H, et al. Multifunctional hydrophobized microparticles for accelerated
49
50 wound healing after endoscopic submucosal dissection. Small. 2019;15:e1901566.
51
52 <https://doi.org/10.1002/sml.201901566>
53
54
55
56
57

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
9. Ito S, Nishiguchi A, Sasaki F, et al. Robust closure of post-endoscopic submucosal dissection perforation by microparticle-based wound dressing. *Mater Sci Eng C Mater Biol Appl*. 2021;123:111993. <https://doi.org/10.1016/j.msec.2021.111993>
10. Kabayama M, Sasaki F, Hidehito M, et al. Effects of sprayable, highly adhesive hydrophobized gelatin microparticles on endoscopic submucosal dissection: a swine model. *Digestion*. 2023;104:137–47. <https://doi.org/10.1159/000526650>
11. Mizuno Y, Mizuta R, Hashizume M, et al. Enhanced sealing strength of a hydrophobically-modified Alaska pollock gelatin-based sealant. *Biomater Sci*. 2017;5:982–9. <https://doi.org/10.1039/c6bm00829a>
12. Nishiguchi A, Kurihara Y, Taguchi T. Underwater-adhesive microparticle dressing composed of hydrophobically-modified Alaska pollock gelatin for gastrointestinal tract wound healing. *Acta Biomater*. 2019;99:387–96. <https://doi.org/10.1016/j.actbio.2019.08.040>
13. Kanai N, Yamato M, Ohki T, et al. Fabricated autologous epidermal cell sheets for the prevention of esophageal stricture after circumferential ESD in a porcine model. *Gastrointest Endosc*. 2012;76:873–81. <https://doi.org/10.1016/j.gie.2012.06.017>
14. Aoki S, Sakata Y, Shimoda R, et al. High-density collagen patch prevents stricture after endoscopic circumferential submucosal dissection of the esophagus: a porcine model. *Gastrointest Endosc*. 2017;85:1076–85. <https://doi.org/10.1016/j.gie.2016.10.012>
15. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. *Bone Marrow Transplant*. 2013;48:452–8. <https://doi.org/10.1038/bmt.2012.244>
16. Leoni G, Neumann PA, Sumagin R, et al. Wound repair: role of immune-epithelial interactions. *Mucosal Immunol*. 2015;8:959–68. <https://doi.org/10.1038/mi.2015.63>
17. Ono S, Fujishiro M, Niimi K, et al. Predictors of postoperative stricture after esophageal endoscopic submucosal dissection for superficial squamous cell neoplasms. *Endoscopy*. 2009;41:661–5. <https://doi.org/10.1055/s-0029-1214867>
18. Hanaoka N, Ishihara R, Takeuchi Y, et al. Intralesional steroid injection to prevent stricture after endoscopic submucosal dissection for esophageal cancer: a controlled prospective study. *Endoscopy*. 2012;44:1007–11. <https://doi.org/10.1055/s-0032-1310107>
19. Neuhaus H. Prevention of strictures after endoscopic resection of esophageal neoplasia. *Gastrointest Endosc*. 2016;84:614–7. <https://doi.org/10.1016/j.gie.2016.05.045>

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
20. Hochberger J, Koehler P, Wedi E, et al. Transplantation of mucosa from stomach to esophagus to prevent stricture after circumferential endoscopic submucosal dissection of early squamous cell. *Gastroenterology*. 2014;146:906–9. <https://doi.org/10.1053/j.gastro.2014.01.063>
 21. Barret M, Beye B, Leblanc S, et al. Systematic review: the prevention of oesophageal stricture after endoscopic resection. *Aliment Pharmacol Ther*. 2015;42:20–39. <https://doi.org/10.1111/apt.13254>
 22. Dua KS, Hogan WJ, Aadam AA, et al. In-vivo oesophageal regeneration in a human being by use of a non-biological scaffold and extracellular matrix. *Lancet*. 2016;388:55–61. [https://doi.org/10.1016/S0140-6736\(15\)01036-3](https://doi.org/10.1016/S0140-6736(15)01036-3)
 23. Arthur MJ, Mann DA, Iredale JP. Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis. *J Gastroenterol Hepatol*. 1998;13 Suppl:S33–8. <https://doi.org/10.1111/jgh.1998.13.s1.33>
 24. Roeb E. Matrix metalloproteinases and liver fibrosis (translational aspects). *Matrix Biol*. 2018;68–69:463–73. <https://doi.org/10.1016/j.matbio.2017.12.012>
 25. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. *J Clin Invest*. 2007;117:524–9. <https://doi.org/10.1172/JCI31487>
 26. Erlewyn-Lajeunesse MD, Hunt LP, Pohunek P, et al. Bronchoalveolar lavage MMP-9 and TIMP-1 in preschool wheezers and their relationship to persistent wheeze. *Pediatr Res*. 2008;64:194–9. <https://doi.org/10.1203/PDR.0b013e318175dd2d>
 27. Thornton KJ, Kamange-Sollo E, White ME, et al. Role of G protein-coupled receptors (GPCR), matrix metalloproteinases 2 and 9 (MMP2 and MMP9), heparin-binding epidermal growth factor-like growth factor (hbEGF), epidermal growth factor receptor (EGFR), erbB2, and insulin-like growth factor 1 receptor (IGF-1R) in trenbolone acetate-stimulated bovine satellite cell proliferation. *J Anim Sci*. 2015;93:4291–301. <https://doi.org/10.2527/jas.2015-9191>
 28. Antunes LA, Antunes LS, Kuchler EC, et al. Analysis of the association between polymorphisms in MMP2, MMP3, MMP9, MMP20, TIMP1, and TIMP2 genes with white spot lesions and early childhood caries. *Int J Paediatr Dent*. 2016;26:310–9. <https://doi.org/10.1111/ipd.12202>
 29. Khokha R, Waterhouse P, Yagel S, et al. Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. *Science*. 1989;243:947–50. <https://doi.org/10.1126/science.2465572>

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
30. Lu X, Duan L, Xie H, et al. Evaluation of MMP-9 and MMP-2 and their suppressor TIMP-1 and TIMP-2 in adenocarcinoma of esophagogastric junction. *Onco Targets Ther.* 2016;9:4343–9. <https://doi.org/10.2147/OTT.S99580>
31. Jalali M, Bayat A. Current use of steroids in management of abnormal raised skin scars. *Surgeon.* 2007;5:175–80. [https://doi.org/10.1016/s1479-666x\(07\)80045-x](https://doi.org/10.1016/s1479-666x(07)80045-x)
32. Ito S, Nishiguchi A, Ichimaru H, et al. Prevention of postoperative adhesion with a colloidal gel based on decyl group-modified Alaska pollock gelatin microparticles. *Acta Biomater.* 2022;149:139–49. <https://doi.org/10.1016/j.actbio.2022.06.014>

Figure Captions

Fig. 1 Scanning electron microscopy image of hMPs

In this study, hydrophobically modified Alaska pollock gelatin is prepared by reductive amination of gelatin and aldehyde. hMPs are prepared using a coacervation method in a water/ethanol mixed solvent.

hMPs: Hydrophobized microparticles

Fig. 2 ESD procedure and grouping in this study

(a) A full circumferential artificial ulcer with a 20-mm-long diameter is created at the lower esophagus (3 cm mouth side from the EG junction) using the ESD technique.

(b) The swine are divided into two groups: the sprayed and non-sprayed. The animals in the sprayed group are sprayed with hMPs on Days 0, 3, and 7 of ESD. The animals in the non-sprayed group underwent endoscopy on the same days.

hMPs: hydrophobized microparticles; ESD: endoscopic submucosal dissection; EG junction: esophagogastric junction

Fig. 3 hMPs can significantly reduce esophageal stricture rate in full circumferential esophageal ESD

After sacrificing on Day 14, the esophageal stricture rate is compared on the basis of macroscopic findings. The esophageal stricture rate is significantly lower in the sprayed group than in the non-sprayed group ($76.11\% \pm 5.03\%$ vs. $90.65\% \pm 1.00\%$, respectively; $p < 0.05$).

hMPs: hydrophobized microparticles; ESD: endoscopic submucosal dissection

Fig. 4 hMPs can decrease inflammatory cell infiltration

Histological observation of the submucosal tissues after 14 days shows that the number of invaded inflammatory cells is lower in the tissues sprayed with hMPs than in the non-sprayed tissue (415.36 ± 16.76 /HPF vs. 559.97 ± 5.50 /HPF, respectively; $p < 0.005$). hMPs: hydrophobized microparticles

Fig. 5. hMPs can suppress the thickening of the muscular layer

Thickening of the muscular layer is significantly suppressed in the sprayed group compared with that in the non-sprayed group (U/NU ratio, 0.90 ± 0.16 vs. 1.79 ± 0.09 , respectively; $p < 0.01$).

hMPs: hydrophobized microparticles, HE: hematoxylin and eosin

1
2
3
4 **Fig. 6 hMPs can decrease the ratio of TIMP-1 to MMP-2 positive cells (TIMP-1/MMP-2 ratio) and TIMP-1**
5 **to MMP-9 positive cells (TIMP-1/MMP-9 ratio)**



6
7
8 The TIMP-1/MMP-2 ratio in the submucosal layer is significantly lower in the sprayed group than in the non-
9 sprayed group (0.39 ± 0.09 vs. 1.97 ± 0.30 , respectively; $p<0.01$). Similarly, the TIMP-1/MMP-9 ratio in the
10 submucosal layer is significantly lower in the sprayed group (1.17 ± 0.43 vs. 4.97 ± 1.16 , respectively; $p<0.05$).

11
12
13 hMPs: hydrophobized microparticles, MMP: matrix metalloproteinase, TIMP-1: tissue inhibitor of
14 metalloproteinases-1
15


16
17
18
19
20 **Fig. 7 Sprayable, tissue-adhesive hMPs may serve as a promising medical intervention to prevent post-**
21 **esophageal ESD stricture**

22
23
24 Our findings show that hMPs can efficiently suppress fibrosis in submucosal tissues via physical and biochemical
25 interactions and prevent post-esophageal ESD stricture.
26

27
28 hMPs: hydrophobized microparticles, ESD: endoscopic submucosal dissection
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65



a



b

